Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3551-3574

  Bäck, Magnus ^a,b,c   Powell, William S ^d   Dahlén, Sven Erik ^a,e   Drazen, Jeffrey M ^a,b   Evans, Jilly F ^a,f   Serhan, Charles N ^a,e   Shimizu, Takao ^a,g   Yokomizo, Takehiko ^a,h   Rovati, G Enrico ^a,i  

^a Nomenclature Subcommittee for Leukotriene Receptors International Union of Basic and Clinical Pharmacology   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MCGILL UNIVERSITY   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f PharmAkea   (United States)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

cancer; cardiovascular; eicosanoids; inflammation; lipoxins; lipoxygenase; LTs; oxoeicosanoids; respiratory

Indexed keywords

5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; AQUAPORIN 4; CHEMERIN RECEPTOR 23; CYSTEINYLLEUKOTRIENE 1 RECEPTOR; CYSTEINYLLEUKOTRIENE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 17; G PROTEIN COUPLED RECEPTOR 32; GLUCOCORTICOID; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR 1; LEUKOTRIENE B4 RECEPTOR 2; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN A; LIPOXIN RECEPTOR; LIPOXYGENASE INHIBITOR; MONTELUKAST; OXOEICOSANOID RECEPTOR; OXOGLUTARATE RECEPTOR; PEPTIDOLEUKOTRIENE; PRANLUKAST; RECEPTOR; UNCLASSIFIED DRUG; ZAFIRLUKAST; LIGAND;

ADD ON THERAPY; ALLERGIC AIRWAY INFLAMMATION; ALLERGIC RHINITIS; ALLERGY; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; BREAST CANCER; BRONCHOCONSTRICTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETIC RETINOPATHY; EXPERIMENTAL PULMONARY FIBROSIS; FOOD ALLERGY; HUMAN; HYPERTENSION; IMPLANT CAPSULAR CONTRACTURE; INFLAMMATION; MILD PERSISTENT ASTHMA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SLEEP DISORDERED BREATHING; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, EICOSANOID; SIGNAL TRANSDUCTION;

EID: 84904596809     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12665     Document Type: Review

References (212)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
3. Aratake Y, Okuno T, Matsunobu T, Saeki K, Takayanagi R, Furuya S, etal. (2012). Helix 8 of leukotriene B4 receptor 1 inhibits ligand-induced internalization. FASEB J 26: 4068-4078.
4. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, etal. (2005). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722.
5. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN, (2007). Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178: 3912-3917.
6. Bae YS, Park JC, He R, Ye RD, Kwak JY, Suh PG, etal. (2003). Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils. Mol Pharmacol 64: 721-730.
7. Barajas-Espinosa A, Ochoa-Cortes F, Moos MP, Ramirez FD, Vanner SJ, Funk CD, (2011). Characterization of the cysteinyl leukotriene 2 receptor in novel expression sites of the gastrointestinal tract. Am J Pathol 178: 2682-2689.
8. Barajas-Espinosa A, Ni NC, Yan D, Zarini S, Murphy RC, Funk CD, (2012). The cysteinyl leukotriene 2 receptor mediates retinal edema and pathological neovascularization in a murine model of oxygen-induced retinopathy. FASEB J 26: 1100-1109.
9. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S, etal. (2013). Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 5: 174ra126.
10. Barrett NA, Rahman OM, Fernandez JM, Parsons MW, Xing W, Austen KF, etal. (2011). Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J Exp Med 208: 593-604.
11. Barrett NA, Fernandez JM, Maekawa A, Xing W, Li L, Parsons MW, etal. (2012). Cysteinyl leukotriene 2 receptor on dendritic cells negatively regulates ligand-dependent allergic pulmonary inflammation. J Immunol 189: 4556-4565.
12. Bäck M, (2007). Leukotriene receptors: crucial components in vascular inflammation. Scientificworldjournal 7: 1422-1439.
13. Bäck M, Hansson GK, (2006). Leukotriene receptors in atherosclerosis. Ann Med 38: 493-502.
14. Bäck M, Norel X, Walch L, Gascard J, Mazmanian G, Dahlén S, etal. (2000). Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. Eur J Pharmacol 401: 381-388.
15. Bäck M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK, (2005). Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 102: 17501-17506.
16. Bäck M, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, etal. (2011). International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 63: 539-584.
17. Bengtsson AM, Jonsson G, Magnusson C, Salim T, Axelsson C, Sjolander A, (2013). The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. BMC Cancer 13: 336.
18. Benned-Jensen T, Rosenkilde M, (2010). Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants. Br J Pharmacol 159: 1092-1105.
19. Blattermann S, Peters L, Ottersbach PA, Bock A, Konya V, Weaver CD, etal. (2012). A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol 8: 631-638.
20. Bondue B, Wittamer V, Parmentier M, (2011a). Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 22: 331-338.
21. Bondue B, Vosters O, de Nadai P, Glineur S, De Henau O, Luangsay S, etal. (2011b). ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia. PLoS Pathog 7: e1002358.
22. Bonnans C, Mainprice B, Chanez P, Bousquet J, Urbach V, (2003). Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium. J Biol Chem 278: 10879-10884.
23. Bonnans C, Fukunaga K, Levy MA, Levy BD, (2006). Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 168: 1064-1072.
24. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, Merritt AS, etal. (2012). Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 109: 935-940.
25. Braido F, Riccio AM, Rogkakou A, Massacane P, Guerra L, Fumagalli F, etal. (2012). Montelukast effects on inflammation in allergic rhinitis: a double blind placebo controlled pilot study. Eur Ann Allergy Clin Immunol 44: 48-53.
26. Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ, etal. (2013). A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122: 608-617.
27. Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Nicosia S, etal. (2003). International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55: 195-227.
28. Brink C, Dahlén SE, Drazen J, Evans JF, Hay DW, Rovati GE, etal. (2004). International Union of Pharmacology XLIV. Nomenclature for the oxoeicosanoid receptor. Pharmacol Rev 56: 149-157.
29. Capra V, Rovati GE, (2014). Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents. Pulm Pharmacol Ther 27: 10-16.
30. Capra V, Nicosia S, Ragnini D, Mezzetti M, Keppler D, Rovati GE, (1998). Identification and characterization of two cysteinyl-leukotriene high affinity binding sites with receptor characteristics in human lung parenchyma. Mol Pharmacol 53: 750-758.
31. Capra V, Accomazzo MR, Ravasi S, Parenti M, Macchia M, Nicosia S, etal. (2003). Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells. Prostaglandins Other Lipid Mediat 71: 235-251.
32. Capra V, Ravasi S, Accomazzo MR, Parenti M, Rovati GE, (2004). CysLT1 signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras. Biochem Pharmacol 67: 1569-1577.
33. Capra V, Ravasi S, Accomazzo MR, Citro S, Grimoldi M, Abbracchio MP, etal. (2005). CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation. J Cell Sci 118 (Pt 23): 5625-5636.
34. Capra V, Ambrosio M, Riccioni G, Rovati GE, (2006). Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 13: 3213-3226.
35. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE, (2007). Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 27: 469-527.
36. Capra V, Back M, Barbieri SS, Camera M, Tremoli E, Rovati GE, (2013). Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev 33: 364-438.
37. Capra V, Carnini C, Accomazzo MR, Di Gennaro A, Fiumicelli M, Borroni E, etal. (2014). Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: signaling through the CysLT2 receptor. J Lipid Res (in press).
38. Carnini C, Accomazzo MR, Borroni E, Vitellaro-Zuccarello L, Durand T, Folco G, etal. (2011). Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J 25: 3519-3528.
39. Cash JL, Hart R, Russ A, Dixon JP, Colledge WH, Doran J, etal. (2008). Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 205: 767-775.
40. Chauhan BF, Ducharme FM, (2012). Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev (5): CD002314.
41. Chauhan BF, Ducharme FM, (2014). Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev (1): CD003137.
42. Chen K, Le Y, Liu Y, Gong W, Ying G, Huang J, etal. (2010). A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses. J Immunol 184: 3331-3335.
43. Chen K, Liu M, Liu Y, Yoshimura T, Shen W, Le Y, etal. (2013). Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest 123: 1694-1704.
44. Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN, (1999). Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest 104: 309-316.
45. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, etal. (2006). The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 58: 463-487.
46. Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, etal. (2012). Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528.
47. Chou RC, Kim ND, Sadik CD, Seung E, Lan Y, Byrne MH, etal. (2010). Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 33: 266-278.
48. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, etal. (2006). The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 25: 4615-4627.
49. Cooke M, Di Consoli H, Maloberti P, Cornejo Maciel F, (2013). Expression and function of OXE receptor, an eicosanoid receptor, in steroidogenic cells. Mol Cell Endocrinol 371: 71-78.
50. Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, etal. (2013). Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A 110: 18232-18237.
51. Czech W, Barbisch M, Tenscher K, Schopf E, Schroder JM, Norgauer J, (1997). Chemotactic 5-oxo-eicosatetraenoic acids induce oxygen radical production, Ca2+-mobilization, and actin reorganization in human eosinophils via a pertussis toxin-sensitive G-protein. J Invest Dermatol 108: 108-112.
52. Dallaire MJ, Ferland C, Page N, Lavigne S, Davoine F, Laviolette M, (2003). Endothelial cells modulate eosinophil surface markers and mediator release. Eur Respir J 21: 918-924.
53. Dalli J, Consalvo AP, Ray V, Di Filippo C, D'Amico M, Mehta N, etal. (2013a). Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J Immunol 190: 6478-6487.
54. Dalli J, Winkler JW, Colas RA, Arnardottir H, Cheng CY, Chiang N, etal. (2013b). Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol 20: 188-201.
55. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, etal. (2013). International union of basic and clinical pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65: 967-986.
56. Demoor T, Bracke KR, Dupont LL, Plantinga M, Bondue B, Roy MO, etal. (2011). The role of ChemR23 in the induction and resolution of cigarette smoke-induced inflammation. J Immunol 186: 5457-5467.
57. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, etal. (2008). Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112: 848-855.
58. Drazen JM, (2003). Leukotrienes in asthma. Adv Exp Med Biol 525: 1-5.
59. Drost AC, Seitz G, Boehmler A, Funk M, Norz KP, Zipfel A, etal. (2012). The G-protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia. Leuk Lymphoma 53: 665-673.
60. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, etal. (2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184: 2611-2619.
61. Eap R, Jacques E, Semlali A, Plante S, Chakir J, (2012). Cysteinyl leukotrienes regulate TGF-beta(1) and collagen production by bronchial fibroblasts obtained from asthmatic subjects. Prostaglandins Leukot Essent Fatty Acids 86: 127-133.
62. Eaton A, Nagy E, Pacault M, Fauconnier J, Back M, (2012). Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression. J Mol Med (Berl) 90: 1223-1231.
63. Enyedi B, Kala S, Nikolich-Zugich T, Niethammer P, (2013). Tissue damage detection by osmotic surveillance. Nat Cell Biol 15: 1123-1130.
64. Forsman H, Onnheim K, Andreasson E, Dahlgren C, (2011). What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4? Scand J Immunol 74: 227-234.
65. Foster HR, Fuerst E, Lee TH, Cousins DJ, Woszczek G, (2013). Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes. PLoS ONE 8: e58305.
66. Fredman G, Van Dyke TE, Serhan CN, (2010). Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 30: 2005-2013.
67. Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, etal. (2013). Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 190: 689-694.
68. Gaudreau R, Le Gouill C, Venne MH, Stankova J, Rola-Pleszczynski M, (2002). Threonine 308 within a putative casein kinase 2 site of the cytoplasmic tail of leukotriene B(4) receptor (BLT1) is crucial for ligand-induced, G-protein-coupled receptor-specific kinase 6-mediated desensitization. J Biol Chem 277: 31567-31576.
69. Goldbart AD, Greenberg-Dotan S, Tal A, (2012). Montelukast for children with obstructive sleep apnea: a double-blind, placebo-controlled study. Pediatrics 130: e575-e580.
70. Gore V, Patel P, Chang CT, Sivendran S, Kang N, Ouedraogo YP, etal. (2013). 5-Oxo-ETE receptor antagonists. J Med Chem 56: 3725-3732.
71. Gotoh M, Okubo K, Hashiguchi K, Wakabayashi K, Kanzaki S, Tanaka N, etal. (2012). Noninvasive biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar pollinosis. Allergy Asthma Proc 33: 459-466.
72. Grant GE, Rokach J, Powell WS, (2009). 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat 89: 98-104.
73. Hallstrand TS, Henderson WR Jr, (2010). An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 10: 60-66.
74. Han J, Jia Y, Takeda K, Shiraishi Y, Okamoto M, Dakhama A, etal. (2010). Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus. Am J Resp Crit Care Med 182: 455-463.
75. Hanson J, Ferreiros N, Pirotte B, Geisslinger G, Offermanns S, (2013). Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A(4). Biochem Pharmacol 85: 1795-1802.
76. Haribabu B, Verghese MW, Steeber DA, Sellars DD, Bock CB, Snyderman R, (2000). Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 192: 433-438.
77. He HQ, Liao D, Wang ZG, Wang ZL, Zhou HC, Wang MW, etal. (2013). Functional characterization of three mouse formyl peptide receptors. Mol Pharmacol 83: 389-398.
78. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, etal. (2004). Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429: 188-193.
79. Hecht I, Rong J, Sampaio AL, Hermesh C, Rutledge C, Shemesh R, etal. (2009). A novel peptide agonist of formyl-peptide receptor-like 1 (ALX) displays anti-inflammatory and cardioprotective effects. J Pharmacol Exp Ther 328: 426-434.
80. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im D-S, etal. (2000). Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275: 30531-30536.
81. Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T, (2009). A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc Natl Acad Sci U S A 106: 21294-21299.
82. Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N, etal. (2002). Identification of a novel human eicosanoid receptor coupled to G(i/o). J Biol Chem 277: 31459-31465.
83. Hosoi T, Sugikawa E, Chikada A, Koguchi Y, Ohnuki T, (2005). TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun 334: 987-995.
84. Houard X, Ollivier V, Louedec L, Michel JB, Bäck M, (2009). Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J 23: 1376-1383.
85. Hoyer FF, Albrecht L, Nickenig G, Muller C, (2012). Selective inhibition of leukotriene receptor BLT-2 reduces vascular oxidative stress and improves endothelial function in ApoE-/- mice. Mol Cell Biochem 359: 25-31.
86. Iikura M, Suzukawa M, Yamaguchi M, Sekiya T, Komiya A, Yoshimura-Uchiyama C, etal. (2005). 5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B(4) induces degranulation. J Allergy Clin Immunol 116: 578-585.
87. Iizuka Y, Okuno T, Saeki K, Uozaki H, Okada S, Misaka T, etal. (2010). Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis. FASEB J 24: 4678-4690.
88. Ingelsson E, Yin L, Bäck M, (2012). Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 129: 702-707 e702.
89. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA, (2007). CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene-dependent mitogenic responses of mast cells. Blood 110: 3263-3270.
90. Jiang Y, Borrelli L, Bacskai BJ, Kanaoka Y, Boyce JA, (2009). P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells. J Immunol 182: 1129-1137.
91. Jones CE, Holden S, Tenaillon L, Bhatia U, Seuwen K, Tranter P, etal. (2003). Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z- eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol Pharmacol 63: 471-477.
92. Kanaoka Y, Maekawa A, Austen KF, (2013). Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 288: 10967-10972.
93. Kazani S, Sadeh J, Bunga S, Wechsler ME, Israel E, (2011). Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. Respir Med 105: 667-673.
94. Kihara Y, Yokomizo T, Kunita A, Morishita Y, Fukayama M, Ishii S, etal. (2010). The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 394: 673-678.
95. Kim ND, Chou RC, Seung E, Tager AM, Luster AD, (2006). A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 203: 829-835.
96. Kiwamoto T, Ishii Y, Morishima Y, Yoh K, Kikuchi N, Haraguchi N, etal. (2011). Blockade of cysteinyl leukotriene-1 receptors suppresses airway remodelling in mice overexpressing GATA-3. Clin Exp Allergy 41: 116-128.
97. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, etal. (2010). Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107: 1660-1665.
98. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN, (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180: 2018-2027.
99. Labat C, Temmar M, Nagy E, Bean K, Brink C, Benetos A, etal. (2013). Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J Hypertens 31: 2251-2258.
100. Laidlaw TM, Boyce JA, (2012). Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 42: 1313-1320.
101. Langlois A, Ferland C, Tremblay GM, Laviolette M, (2006). Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol 118: 113-119.
102. Langlois A, Chouinard F, Flamand N, Ferland C, Rola-Pleszczynski M, Laviolette M, (2009). Crucial implication of protein kinase C (PKC)-delta, PKC-zeta, ERK-1/2, and p38 MAPK in migration of human asthmatic eosinophils. J Leukoc Biol 85: 656-663.
103. Lee JW, Kim GY, Kim JH, (2012). Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. Biochem Biophys Res Commun 420: 428-433.
104. Lee TH, Austen KF, Corey EJ, Drazen JM, (1984). Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A 81: 4922-4925.
105. Li RC, Haribabu B, Mathis SP, Kim J, Gozal D, (2011). Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am J Respir Crit Care Med 184 (1): 124-131.
106. Li YS, Wu P, Zhou XY, Chen JG, Cai L, Wang F, etal. (2008). Formyl-peptide receptor like 1: a potent mediator of the Ca2+ release-activated Ca2+ current ICRAC. Arch Biochem Biophys 478: 110-118.
107. Luangsay S, Wittamer V, Bondue B, De Henau O, Rouger L, Brait M, etal. (2009). Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol 183: 6489-6499.
108. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, etal. (2010). FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 24: 4240-4249.
109. Maekawa A, Kanaoka Y, Xing W, Austen KF, (2008). Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105: 16695-16700.
110. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y, (2009). GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci U S A 106: 11685-11690.
111. Maekawa A, Xing W, Austen KF, Kanaoka Y, (2010). GPR17 regulates immune pulmonary inflammation induced by house dust mites. J Immunol 185: 1846-1854.
112. Magnusson C, Ehrnstrom R, Olsen J, Sjolander A, (2007). An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res 67: 9190-9198.
113. Magnusson C, Mezhybovska M, Lorinc E, Fernebro E, Nilbert M, Sjolander A, (2010). Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer 46: 826-835.
114. Magnusson C, Liu J, Ehrnstrom R, Manjer J, Jirstrom K, Andersson T, etal. (2011). Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. Int J Cancer 129: 9-22.
115. Mamedova L, Capra V, Accomazzo MR, Gao ZG, Ferrario S, Fumagalli M, etal. (2005). CysLT(1) leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol 71: 115-125.
116. Mathis SP, Jala VR, Lee DM, Haribabu B, (2010). Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol 185: 3049-3056.
117. Matsunaga Y, Fukuyama S, Okuno T, Sasaki F, Matsunobu T, Asai Y, etal. (2013). Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J 27: 3306-3314.
118. Mazzocchi M, Dessy LA, Alfano C, Scuderi N, (2012). Effects of zafirlukast on capsular contracture: long-term results. Int J Immunopathol Pharmacol 25: 935-944.
119. McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson C, (2002). Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J 16: 1817-1819.
120. Miyahara N, Takeda K, Miyahara S, Matsubara S, Koya T, Joetham A, etal. (2005). Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 172: 161-167.
121. Monteiro AP, Pinheiro CS, Luna-Gomes T, Alves LR, Maya-Monteiro CM, Porto BN, etal. (2011). Leukotriene B4 mediates neutrophil migration induced by heme. J Immunol 186: 6562-6567.
122. Muro S, Hamid Q, Olivenstein R, Taha R, Rokach J, Powell WS, (2003). 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin. J Allergy Clin Immunol 112: 768-774.
123. Nagy E, Andersson DC, Caidahl K, Eriksson MJ, Eriksson P, Franco-Cereceda A, etal. (2011). Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123: 1316-1325.
124. Nakamura M, Shimizu T, (2011). Leukotriene receptors. Chem Rev 111: 6231-6298.
125. Ni NC, Yan D, Ballantyne LL, Barajas-Espinosa A, St Amand T, Pratt DA, etal. (2011). A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther 339: 768-778.
126. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, etal. (2005). A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. Cancer Res 65: 732-742.
127. Nonaka Y, Hiramoto T, Fujita N, (2005). Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337: 281-288.
128. Norgauer J, Barbisch M, Czech W, Pareigis J, Schwenk U, Schroder JM, (1996). Chemotactic 5-oxo-icosatetraenoic acids activate a unique pattern of neutrophil responses. Analysis of phospholipid metabolism, intracellular Ca2+ transients, actin reorganization, superoxide-anion production and receptor up-regulation. Eur J Biochem 236: 1003-1009.
129. Norling LV, Dalli J, Flower RJ, Serhan CN, Perretti M, (2012). Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol 32: 1970-1978.
130. O'Flaherty JT, Kuroki M, Nixon AB, Wijkander J, Yee E, Lee SL, etal. (1996a). 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway. J Biol Chem 271: 17821-17828.
131. O'Flaherty JT, Kuroki M, Nixon AB, Wijkander J, Yee E, Lee SL, etal. (1996b). 5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes. J Immunol 157: 336-342.
132. O'Flaherty JT, Taylor JS, Kuroki M, (2000). The coupling of 5-oxo-eicosanoid receptors to heterotrimeric G proteins. J Immunol 164: 3345-3352.
133. O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, etal. (2005). 5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta 1736: 228-236.
134. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN, (2010). Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 285: 3451-3461.
135. Okuno T, Ago H, Terawaki K, Miyano M, Shimizu T, Yokomizo T, (2003). Helix 8 of the leukotriene B4 receptor is required for the conformational change to the low affinity state after G-protein activation. J Biol Chem 278: 41500-41509.
136. Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T, (2008). 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 205: 759-766.
137. Oyoshi MK, He R, Kanaoka Y, ElKhal A, Kawamoto S, Lewis CN, etal. (2012a). Eosinophil-derived leukotriene C4 signals via type 2 cysteinyl leukotriene receptor to promote skin fibrosis in a mouse model of atopic dermatitis. Proc Natl Acad Sci U S A 109: 4992-4997.
138. Oyoshi MK, He R, Li Y, Mondal S, Yoon J, Afshar R, etal. (2012b). Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. Immunity 37: 747-758.
139. Pamplona FA, Ferreira J, Menezes de Lima O Jr, Duarte FS, Bento AF, Forner S, etal. (2012). Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A 109: 21134-21139.
140. Parmentier CN, Fuerst E, McDonald J, Bowen H, Lee TH, Pease JE, etal. (2012). Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. J Allergy Clin Immunol 129: 1136-1142.
141. Paruchuri S, Tashimo H, Feng C, Maekawa A, Xing W, Jiang Y, etal. (2009). Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206: 2543-2555.
142. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106. PMID: 24234439.
143. Peebles RS Jr, (2013). A new horizon in asthma: inhibiting ILC function. Sci Transl Med 5: 174fs177.
144. Planaguma A, Domenech T, Jover I, Ramos I, Sentellas S, Malhotra R, etal. (2013). Lack of activity of 15-epi-lipoxin A4 on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol 173: 298-309.
145. de Poorter C, Baertsoen K, Lannoy V, Parmentier M, Springael JY, (2013). Consequences of ChemR23 heteromerization with the chemokine receptors CXCR4 and CCR7. PLoS ONE 8: e58075.
146. Poulin S, Thompson C, Thivierge M, Veronneau S, McMahon S, Dubois CM, etal. (2011). Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells. Clin Exp Allergy 41: 204-217.
147. Powell WS, Gravelle F, Gravel S, (1992). Metabolism of 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydrogenase in human polymorphonuclear leukocytes. J Biol Chem 267: 19233-19241.
148. Powell WS, Gravel S, MacLeod RJ, Mills E, Hashefi M, (1993). Stimulation of human neutrophils by 5-oxo-6,8,11,14-eicosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor. J Biol Chem 268: 9280-9286.
149. Powell WS, Chung D, Gravel S, (1995). 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol 154: 4123-4132.
150. Powell WS, MacLeod RJ, Gravel S, Gravelle F, Bhakar A, (1996). Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol 156: 336-342.
151. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, etal. (2013). Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol 131: 763-771.
152. Provost V, Langlois A, Chouinard F, Rola-Pleszczynski M, Chakir J, Flamand N, etal. (2012). Leukotriene D4 and interleukin-13 cooperate to increase the release of eotaxin-3 by airway epithelial cells. PLoS ONE 7: e43544.
153. Qi AD, Harden TK, Nicholas RA, (2013). Is GPR17 a P2Y/Leukotriene receptor? Examination of uracil nucleotides, nucleotide-sugars, and cysteinyl-leukotrienes as agonists of GPR17. J Pharmacol Exp Ther 347: 38-46.
154. Qi LL, Fang SH, Shi WZ, Huang XQ, Zhang XY, Lu YB, etal. (2011). CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes. Life Sci 88: 50-56.
155. Qu X, Zhang X, Yao J, Song J, Nikolic-Paterson DJ, Li J, (2012). Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol. doi: 10.1002/path.4050.
156. Ravasi S, Capra V, Mezzetti M, Nicosia S, Rovati GE, (2000). A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. Mol Pharmacol 57: 1182-1189.
157. Ravasi S, Capra V, Panigalli T, Rovati GE, Nicosia S, (2002). Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol 63: 1537-1546.
158. Ravasi S, Citro S, Viviani B, Capra V, Rovati GE, (2006). CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation. Respir Res 7: 42.
159. Recchiuti A, Serhan CN, (2012). Pro-resolving lipid mediators (SPMs) and their actions in regulating miRNA in novel resolution circuits in inflammation. Front Immunol 3: 298.
160. Recchiuti A, Krishnamoorthy S, Fredman G, Chiang N, Serhan CN, (2011). MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J 25: 544-560.
161. Riviere S, Challet L, Fluegge D, Spehr M, Rodriguez I, (2009). Formyl peptide receptor-like proteins are a novel family of vomeronasal chemosensors. Nature 459 (7246): 574-577.
162. Sadik CD, Kim ND, Iwakura Y, Luster AD, (2012). Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcgammaR signaling. Proc Natl Acad Sci U S A 109: E3177-E3185.
163. Sakata K, Bäck M, (2002). Receptor preferences of cysteinyl-leukotrienes in the guinea pig lung parenchyma. Eur J Pharmacol 436: 119-126.
164. Samuelsson B, (1983). Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575.
165. Schwenk U, Schroder JM, (1995). 5-Oxo-eicosanoids are potent eosinophil chemotactic factors. Functional characterization and structural requirements. J Biol Chem 270: 15029-15036.
166. Scott JP, Peters-Golden M, (2013). Antileukotriene agents for the treatment of lung disease. Am J Resp Crit Care Med 188: 538-544.
167. Seo JM, Park S, Kim JH, (2012). Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2. J Biol Chem 287: 13840-13849.
168. Serhan CN, (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.
169. Serhan CN, (2011). The resolution of inflammation: the devil in the flask and in the details. FASEB J 25: 1441-1448.
170. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, etal. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196: 1025-1037.
171. Sharma RK, Chheda Z, Jala VR, Haribabu B, (2013). Expression of leukotriene B4 receptor-1 on CD8+ T cells is required for their migration into tumors to elicit effective antitumor immunity. J Immunol 191: 3462-3470.
172. Shen Y, Xu Z, Shen K, (2011). Urinary leukotriene E4, obesity, and adenotonsillar hypertrophy in Chinese children with sleep disordered breathing. Sleep 34: 1135-1141.
173. Shen Y, Xu Z, Huang Z, Xu J, Qin Q, Shen K, (2012). Increased cysteinyl leukotriene concentration and receptor expression in tonsillar tissues of Chinese children with sleep-disordered breathing. Int Immunopharmacol 13: 371-376.
174. Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, etal. (2012). Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res 1484: 57-67.
175. Shimbori C, Shiota N, Okunishi H, (2011). Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol 650: 424-430.
176. Snyder DW, Krell RD, (1984). Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea. J Pharmacol Exp Ther 231: 616-622.
177. Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo JM, etal. (2009). Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 29: 3875-3884.
178. Sordi R, Menezes-de-Lima O Jr, Horewicz V, Scheschowitsch K, Santos LF, Assreuy J, (2013). Dual role of lipoxin A in pneumosepsis pathogenesis. Int Immunopharmacol 17: 283-292.
179. Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, etal. (2013). Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen 18: 599-609.
180. Sozzani S, Zhou D, Locati M, Bernasconi S, Luini W, Mantovani A, etal. (1996). Stimulating properties of 5-oxo-eicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3. J Immunol 157: 4664-4671.
181. Stamatiou PB, Chan CC, Monneret G, Ethier D, Rokach J, Powell WS, (2004). 5-oxo-6,8,11,14-eicosatetraenoic acid stimulates the release of the eosinophil survival factor granulocyte/macrophage colony-stimulating factor from monocytes. J Biol Chem 279: 28159-28164.
182. Stanke-Labesque F, Moliere P, Bessard J, Laville M, Vericel E, Lagarde M, (2008). Effect of dietary supplementation with increasing doses of docosahexaenoic acid on neutrophil lipid composition and leukotriene production in human healthy volunteers. Br J Nutr 100: 829-833.
183. Stanke-Labesque F, Bäck M, Lefebvre B, Tamisier R, Baguet JP, Arnol N, etal. (2009). Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 124: 364-370, 370 e361-362.
184. Stanke-Labesque F, Pepin JL, de Jouvencel T, Arnaud C, Baguet JP, Petri MH, etal. (2012). Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res 53: 1944-1951.
185. Stanke-Labesque F, Pepin JL, Gautier-Veyret E, Levy P, Bäck M, (2014). Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res 101: 187-193.
186. Sturm GJ, Schuligoi R, Sturm EM, Royer JF, Lang-Loidolt D, Stammberger H, etal. (2005). 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils. J Allergy Clin Immunol 116: 1014-1019.
187. Sundaram S, Ghosh J, (2006). Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem Biophys Res Commun 339: 93-98.
188. Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD, (2000). BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med 192: 439-446.
189. Takahashi M, Taniuchi S, Soejima K, Sudo K, Hatano Y, Kaneko K, (2014). New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy. Allergy Asthma Clin Immunol 10: 3.
190. Takeda S, Yamamoto A, Haga T, (2002). Identification of a G protein-coupled receptor for 5-oxo-eicosatetraenoic acid. Biomed Res 23: 101-108.
191. Talahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA, (2010). Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci 51: 1699-1708.
192. Terawaki K, Yokomizo T, Nagase T, Toda A, Taniguchi M, Hashizume K, etal. (2005). Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 175: 4217-4225.
193. Tsaoussoglou M, Lianou L, Maragozidis P, Hatzinikolaou S, Mavromati M, Orologas N, etal. (2012). Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea. Sleep Med 13: 879-885.
194. Verriere V, Higgins G, Al-Alawi M, Costello RW, McNally P, Chiron R, etal. (2012). Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia. PLoS ONE 7: e37746.
195. Waki H, Hendy EB, Hindmarch CC, Gouraud S, Toward M, Kasparov S, etal. (2013). Excessive leukotriene B4 in nucleus tractus solitarii is prohypertensive in spontaneously hypertensive rats. Hypertension 61: 194-201.
196. Walch L, Norel X, Bäck M, Gascard JP, Dahlen SE, Brink C, (2002). Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle. Br J Pharmacol 137: 1339-1345.
197. Wang L, Du C, Lv J, Wei W, Cui Y, Xie X, (2011). Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 187: 2336-2345.
198. Wei JD, Kim JY, Kim JH, (2011). BLT2 phosphorylation at Thr355 by Akt is necessary for BLT2-mediated chemotaxis. FEBS Lett 585: 3501-3506.
199. Wei JD, Kim JY, Kim AK, Jang SK, Kim JH, (2013). RanBPM acts as a negative regulator of BLT2 to attenuate BLT2-mediated cell motility. J Biol Chem 288: 26753-26763.
200. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, etal. (2003). Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198: 977-985.
201. Wittamer V, Gregoire F, Robberecht P, Vassart G, Communi D, Parmentier M, (2004). The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem 279: 9956-9962.
202. Wittenberger T, Hellebrand S, Munck A, Kreienkamp HJ, Schaller HC, Hampe W, (2002). GPR99, a new G protein-coupled receptor with homology to a new subgroup of nucleotide receptors. BMC Genomics 3: 17.
203. Woszczek G, Chen LY, Alsaaty S, Nagineni S, Shelhamer JH, (2010). Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists. J Immunol 184: 2219-2225.
204. Wu L, Liu ZJ, Miao S, Zou LB, Cai L, Wu P, etal. (2013). Lipoxin A ameliorates cerebral ischaemia/reperfusion injury through upregulation of nuclear factor erythroid 2-related factor 2. Neurol Res 35: 968-975.
205. Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, etal. (2010). Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol 160: 399-409.
206. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, etal. (2009). International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 61: 119-161.
207. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T, (1997). A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387 (6633): 620-624.
208. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T, (2000). A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 192: 421-432.
209. Yokota Y, Inoue H, Matsumura Y, Nabeta H, Narusawa M, Watanabe A, etal. (2012). Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems. Blood 120: 3444-3454.
210. Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, etal. (2013). HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther 346: 328-341.
211. Zhao C, Zhao B, Zhang X, Huang X, Shi W, Liu H, etal. (2011). Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats. Neuroscience 189: 1-11.
212. Zhu J, Bandi V, Qiu S, Figueroa DJ, Evans JF, Barnes N, etal. (2012). Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest 142: 347-357.